Q4 2024 Earnings Call Transcript March 25, 2025 X4 Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0 ...

In the assessment of 12-month price targets, analysts unveil insights for X4 Pharmaceuticals, presenting an average target of ...

Qualcomm has confirmed that it'll be holding a launch event this week, and the company says we should brace for new ...

The GameSir X4 Aileron is a mobile controller purpose-built for cloud gaming on an Android phone, turning your device into a ...

Phase 3 4WARD trial in chronic neutropenia now activated at ~90% of targeted trial sites; full enrollment expected in 3Q or ...

X4 Pharmaceuticals Inc (XFOR) navigates a challenging landscape with strategic cost reductions and promising product ...

What to expect from MediaTek Dimensity 9400e: flagship-tier performance, improved efficiency, and a strategic push into the ...

X4 Pharmaceuticals highlights 2024 as transformative with XOLREMDI's U.S. launch, international expansion, & Phase 3 trial progress.

BOSTON (AP) — BOSTON (AP) — X4 Pharmaceuticals, Inc. (XFOR) on Tuesday reported a loss of $39.8 million in its fourth quarter. On a per-share basis, the Boston-based company said it had a loss of 20 ...

Qualcomm has officially announced a launch event on 2 April, hinting at the arrival of a flagship product. While the company ...

Before thousands of people flock to downtown Salt Lake City to attend the Qualtrics X4 summit, the Provo-born company on ...